The Leukemia & Lymphoma Society (LLS) and the Knight Cancer Institute at Oregon Health & Science University are leading a pioneering collaboration to develop a precision medicine approach to improve outcomes for patients with acute myeloid leukemia (AML), a particularly devastating cancer of the blood and bone marrow. LLS provided $8.2 million to fund Beat AML and here is how the collaboration will work:

1. In coordination with the Knight Cancer Institute, Stanford University, UT Southwestern Medical Center and Huntsman Cancer Institute will collect data from 900 AML patient samples within 3 years.

2. Illumina will perform genetic sequencing to identify mutations in the patient samples collected.

3. Intel will work with Knight Cancer’s bioinformatics team to apply its technology to accelerate computational analysis of the mutation data collected.

4. Drug and biotech companies will work with the collaboration to test drug compounds that target mutations suspected of driving disease progression. Array BioPharma will be first to test a therapeutic.